Minerva Neurosciences (NERV) Projected to Post Quarterly Earnings on Thursday

Minerva Neurosciences (NASDAQ:NERV) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter.

Minerva Neurosciences Stock Down 1.6 %

Shares of NASDAQ:NERV opened at $1.79 on Tuesday. The stock has a market cap of $12.52 million, a price-to-earnings ratio of -4.07 and a beta of 0.12. Minerva Neurosciences has a 12-month low of $1.77 and a 12-month high of $7.53. The business’s 50 day moving average is $2.18 and its 200 day moving average is $2.41.

Analyst Ratings Changes

NERV has been the topic of several analyst reports. StockNews.com started coverage on Minerva Neurosciences in a research report on Saturday. They set a “sell” rating on the stock. HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.